ClinicalTrials.gg
CompletedNCT06429059Updated Oct 27, 2026Results posted

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

A Phase 2 interventional study of Astaxanthin and Protandim in Amyotrophic Lateral Sclerosis ALS, sponsored by Duke University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Duke University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
118th of 307
50 · median 33
Started
2024
with 19 others
Phase 2
89 of 440
8 open now
Registered
361st of 440
by date
Lead sponsor
8 of 440
Duke University

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 118th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2024, is one of 89 in phase 2, and was the 361st registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

GenieUs developed an analysis platform that will be tested to separate study participants with ALS into four categories based on blood work. These general categories are neuroinflammation, oxidative stress, impaired autophagy \& axonal transport, and mitochondrial dysfunction. Once a disease category is established, participants in this study will receive one of four individualized supplements for 6 months and we will determine whether these are slowing ALS progression: Astaxanthin will be given for the category of neuroinflammation, Protandim for oxidative stress, Melatonin for impaired autophagy and MitoQ for mitochondrial dysfunction. During the first 3 months, participants will have routine monitoring and in months 3 through 9 they will receive the assigned supplement.

Read the detailed description

This will be a widely inclusive, largely remote/virtual, two-center, open-label pilot trial utilizing 50 participants as their own controls. Following informed consent and screening, participants will provide demographics, disease characteristics, co-morbidities, and concomitant medications. They will have a baseline ALSFRS-R score obtained and blood will be drawn for DIGAP classification, PBMCs (which will be used to generate iPSCs from which motor neurons and/or microglia can be generated), baseline mechanistic biomarkers and baseline neurofilament light chain. A urine pregnancy test will be obtained for pre-menopausal females who have not had one by their own doctor in the past 7 days. Each month after that, they will be contacted by phone by study coordinators to review adverse events, new co-morbidities, and concomitant medications, and to generate a new ALSFRS-R score. At month 3, DIGAP classification will be revealed to each participant and based on this, they will receive 1 of 4 treatments. They will take their assigned treatment for 6 months. At months 3, 5 and 9 they will be asked to return for in person blood draws for repeat mechanistic biomarkers and neurofilament light chain measurements. All of the described blood tests and investigational treatments are being performed exclusively for research purposes.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis ALS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged at least 18 years.
  2. Sporadic or familial ALS diagnosed as per Gold Coast Criteria.
  3. Patient is able to understand and express (in the opinion of the site investigator).
  4. Patient is able to read and write English.
  5. Patient is expected to survive for the duration of the trial.
  6. Able to swallow tablets at enrollment and expected to be able to swallow tablets for the duration of the trial.
  7. Women must not be pregnant (will have evidence of a negative pregnancy test obtained by study team at baseline, or by local physician within past 7 days or be )
  8. Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate methods) for the duration of the study and three months after study completion. Adequate contraception includes abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception, or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.

Exclusion criteria

Exclusion Criteria:

  1. Actively or recently (within past 30 days) participating in another intervention trial.
  2. Currently or recently (within 30 days) taking any of the 4 treatments being used in this trial.
  3. Prior side effects from any of the 4 investigational treatments being used in this trial.
  4. Patient has a medical or psychiatric illness that could in the investigator's opinion interfere with the patient's ability to participate in this study.
  5. Pregnant women or women currently breastfeeding.
  6. shorter than the duration of the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Neuroinflammation

    Study participants in this category are expected to have inflammation in their brains and spinal cords.

    Drug: Astaxanthin

  • Experimental
    Oxidative Stress

    Study participants in this category are expected to have too many damaging "free radical" chemicals in their brains and spinal cords.

    Drug: Protandim

  • Experimental
    Impaired Autophagy and Axonal Transport

    Study participants in this category are expected to have motor neurons that have trouble transporting materials up and down their length, and/or trouble with the turnover of damaged proteins and intracellular structures.

    Drug: Melatonin

  • Experimental
    Mitochondrial Dysfunction

    Study participants in this category are expected to have motor neurons that are unable to produce normal amounts of energy.

    Drug: MitoQ

Interventions

  • DrugAstaxanthineStudies of AstaxanthineAstaxanthine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Astaxanthin is a red-orange natural pigment belonging to a group of carotenoids called xanthophylls. In nature, astaxanthin is synthesized by microalgae and phytoplankton and biomagnifies in higher marine animals through the food chain. Natural astaxanthin is available as capsules, soft gels, tablets, powders, biomass, creams, energy drinks, oils and extracts and often contains other carotenoids. The compound is available as a United States Pharmacopeia (USP) verified supplement which ensures federally recognized standards for quality and purity (https://www.quality-supplements.org/verified-products/verified-products-listings).

  • Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.

  • Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.

  • DrugMitoquinoneStudies of MitoquinoneMitoquinone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The active ingredient in MitoQ is ubiquinone, the same as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting mitochondria in cultured cells. It can be administered orally and, at least in animals, can cross the blood brain barrier and accumulate in brain mitochondria.

06

What researchers measure

Primary outcomes

  1. ALS Functional Rating Scale, Revised (ALSFRS-R)

    A quickly administered (five minute) ordinal rating scale (ratings 0-4) used to determine patients' assessments of their capability and independence in 12 functional activities. The total score ranges from 0 (maximum disability) to 48 (normal function). A higher score indicates greater function.

    Time frame: Baseline, month 3, month 5, and month 9

Secondary outcomes

  1. Neurofilament Light Chain Levels

    Neurofilament light chain levels are elevated in the spinal fluid and the blood of patients with ALS and other neurodegenerative diseases, and higher levels predict more severe disease progression. These levels rise dramatically when asymptomatic carriers of ALS-causing genetic mutations begin to convert to an ALS phenotype.

    Time frame: Baseline, month 3, month 5 (2 months into treatment) and month 9 (6 months into treatment)

  2. Neuroinflammation Measured by C-reactive Protein (CRP)

    Used to measure neuroinflammation. CRPs are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.

    Time frame: Baseline, 3 months, 5 months and 9 months

  3. Neuroinflammation Measured by Monocyte Chemoattractant Protein-1 (MCP-1), Also Known as CCL2

    Used to measure neuroinflammation. CCL2s are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.

    Time frame: Baseline, 3 months, 5 months and 9 months

  4. Oxidative Stress Measured by Total Antioxidant Capacity (TAC)

    Used to measure oxidative stress.

    Time frame: Baseline, 3 months, 5 months, and 9 months

  5. Oxidative Stress Measured by Uric Acid Levels.

    Uric acid is an antioxidant and levels of uric acid have been reported to be lower in ALS subjects and correlated with progression. It has also been shown to be responsive to treatments in trials

    Time frame: Baseline, 3 months, 5 months, and 9 months

  6. Mitochondrial Dysfunction Measured by Lactate

    Compromised mitochondrial oxidative phosphorylation shifts the cellular bioenergetic system to anaerobic respiration and increases the level of lactate. Lactate has been used as a biomarker for mitochondrial disease in many previous studies.

    Time frame: Baseline, 3 months, 5 months, and 9 months

Other outcomes

  1. Impaired Autophagy Measured by Beclin-1

    To measure impaired autophagy, we will use Beclin-1. This highly conserved eukaryotic protein has a major regulatory role in autophagy. It is a component of the phosphatidylinositol-3-kinase (PI3K) complex which mediates vesicle-trafficking thereby inducing autophagy. Beclin-1 dysfunction has been implicated in many disorders, including cancer and neurodegenerative diseases.

    Time frame: Baseline, 3 months, 5 months, and 9 months

  2. Neuroinflammation Measured by Chitotriosidase (CHIT1)

    Used to measure neuroinflammation. CHIT1 is known to be abnormal in patients with ALS, its levels correlate with disease progression and they can be altered by drugs in trials.

    Time frame: Baseline, 3 months, 5 months and 9 months

07

Results

Posted Oct 27, 2026

Participant flow

Participants were recruited from the Duke and Temple ALS Clinic populations in 2024.

Participant flow — Overall Study
MilestoneNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Started3151418
Completed1151314
Not completed2014
Withdrew: Death0012
Withdrew: Lost to follow-up1000
Withdrew: Withdrawal by subject1002

Outcome measures

PrimaryALS Functional Rating Scale, Revised (ALSFRS-R)

A quickly administered (five minute) ordinal rating scale (ratings 0-4) used to determine patients' assessments of their capability and independence in 12 functional activities. The total score ranges from 0 (maximum disability) to 48 (normal function). A higher score indicates greater function.

Time frame:
Baseline, month 3, month 5, and month 9
Reported as:
Mean · score on a scale
ALS Functional Rating Scale, Revised (ALSFRS-R)
score on a scaleNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Baseline34.3 ± 6.132.1 ± 9.736.8 ± 6.436.1 ± 6.7
3 months32.5 ± 7.831.1 ± 9.534.4 ± 5.334.1 ± 10.2
5 months28.5 ± 0.729.1 ± 9.234.2 ± 5.233.1 ± 9.7
9 months26.0 ± NA28.0 ± 9.030.8 ± 6.433.0 ± 6.5
Statistical analysis
  • Neuroinflammation vs Oxidative Stress vs Impaired Autophagy and Axonal Transport vs Mitochondrial Dysfunction · Wilcoxon (Mann-Whitney) · p = 0.5592 (Two-sided Wilcoxon signed-rank test on the within-subject difference (on-treatment slope minus pre-treatment slope). This is a single pre-specified comparison; no multiple-comparisons adjustment was applied.) · Median difference (net): -0.1242 · 95% CI -0.5296 to 0.3103Nominal significance threshold alpha = 0.05.
SecondaryNeurofilament Light Chain Levels

Neurofilament light chain levels are elevated in the spinal fluid and the blood of patients with ALS and other neurodegenerative diseases, and higher levels predict more severe disease progression. These levels rise dramatically when asymptomatic carriers of ALS-causing genetic mutations begin to convert to an ALS phenotype.

Time frame:
Baseline, month 3, month 5 (2 months into treatment) and month 9 (6 months into treatment)
Reported as:
Mean · log (pg/mL)
Neurofilament Light Chain Levels
log (pg/mL)NeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Baseline4.4 ± 1.04.6 ± 0.84.5 ± 0.94.6 ± 1.0
3 months4.5 ± 0.64.7 ± 0.84.6 ± 0.84.5 ± 1.0
5 months4.6 ± 0.74.6 ± 0.84.5 ± 0.94.5 ± 1.0
9 months5.5 ± NA4.6 ± 0.84.5 ± 0.94.3 ± 1.1
Statistical analysis
  • Neuroinflammation vs Oxidative Stress vs Impaired Autophagy and Axonal Transport vs Mitochondrial Dysfunction · Mixed Models Analysis · p = 0.672 (Two-sided test of the SPDY main effect (slope = 0) from a linear mixed-effects model. P-values were adjusted using the Benjamin-Hochberg false discovery rate procedure. Nominal significance threshold alpha = 0.05.) · Slope: -0.00020 · 95% CI -0.00113 to 0.00073Estimate represents the daily rate of change in NfL (log) (log\[pg/mL\]) across the full study period, modeled with SPDY (days since supplement initiation) as a continuous predictor. A negative value indicates decreasing NfL (log) over time.
SecondaryNeuroinflammation Measured by C-reactive Protein (CRP)

Used to measure neuroinflammation. CRPs are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.

Time frame:
Baseline, 3 months, 5 months and 9 months
Reported as:
Mean · ng/dL
Neuroinflammation Measured by C-reactive Protein (CRP)
ng/dLNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Baseline1469.8 ± 815.02152.9 ± 1531.91126.8 ± 1094.41502.8 ± 1195.0
3 months5113.4 ± NA1662.0 ± 1377.6878.2 ± 852.51882.0 ± 1402.3
5 months2120.3 ± 2422.92621.2 ± 1931.92308.4 ± 2373.91440.8 ± 1582.5
9 months1685.9 ± NA7900.4 ± 8769.42388.5 ± 2525.56351.9 ± 11469.2
Statistical analysis
  • Neuroinflammation vs Oxidative Stress vs Impaired Autophagy and Axonal Transport vs Mitochondrial Dysfunction · Mixed Models Analysis · p = <0.001 (Two-sided test of the SPDY main effect (slope = 0) from a linear mixed-effects model. P-values were adjusted using the Benjamini-Hochberg false discovery rate (FDR) procedure; the value reported is the FDR-adjusted q-value.) · Slope: 21.170 · 95% CI 12.585 to 29.755Estimate represents the daily rate of change in CRP (ng/mL) across the full study period, modeled with SPDY (days since supplement initiation) as a continuous predictor. A positive value indicates increasing CRP over time.
SecondaryNeuroinflammation Measured by Monocyte Chemoattractant Protein-1 (MCP-1), Also Known as CCL2

Used to measure neuroinflammation. CCL2s are known to be abnormal in patients with ALS, their levels correlate with disease progression and they can be altered by drugs in trials.

Time frame:
Baseline, 3 months, 5 months and 9 months
Reported as:
Mean · pg/mL
Neuroinflammation Measured by Monocyte Chemoattractant Protein-1 (MCP-1), Also Known as CCL2
pg/mLNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Baseline443.3 ± 34.0397.6 ± 150.2336.3 ± 112.4366.9 ± 118.1
3 months373.5 ± 31.8368.2 ± 112.0297.6 ± 97.9399.1 ± 145.1
5 months275.0 ± 50.9328.8 ± 153.2291.6 ± 103.8353.1 ± 195.0
9 months184.0 ± NA224.7 ± 63.3187.2 ± 33.4239.0 ± 92.9
Statistical analysis
  • Neuroinflammation vs Oxidative Stress vs Impaired Autophagy and Axonal Transport vs Mitochondrial Dysfunction · Mixed Models Analysis · p = <0.001 (Two-sided test of the SPDY main effect (slope = 0) from a linear mixed-effects model. P-values were adjusted using the Benjamini-Hochberg false discovery rate (FDR) procedure; the value reported is the FDR-adjusted q-value.) · Slope: -0.626 · 95% CI -0.801 to -0.451Estimate represents the daily rate of change in CCL2 (pg/mL) across the full study period, modeled with SPDY (days since supplement initiation) as a continuous predictor. A negative value indicates decreasing CCL2 over time.
SecondaryOxidative Stress Measured by Total Antioxidant Capacity (TAC)

Used to measure oxidative stress.

Time frame:
Baseline, 3 months, 5 months, and 9 months
Reported as:
Mean · mmol/L
Oxidative Stress Measured by Total Antioxidant Capacity (TAC)
mmol/LNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Baseline196.3 ± 23.8190.5 ± 46.2203.2 ± 66.0192.5 ± 35.4
3 months181.2 ± 83.1148.9 ± 90.9172.2 ± 60.2157.3 ± 88.8
5 months259.0 ± 2.8294.0 ± 71.9263.3 ± 61.6304.8 ± 113.0
9 months296.9 ± NA294.7 ± 71.9273.2 ± 103.9299.6 ± 44.5
Statistical analysis
  • Neuroinflammation vs Oxidative Stress vs Impaired Autophagy and Axonal Transport vs Mitochondrial Dysfunction · Mixed Models Analysis · p = <0.001 (Two-sided test of the SPDY main effect (slope = 0) from a linear mixed-effects model. P-values were adjusted using the Benjamin-Hochberg false discovery rate (FDR) procedure. Nominal significance threshold alpha = 0.05.) · Slope: 0.500 · 95% CI 0.356 to 0.644Estimate represents the daily rate of change in TAC (mmol/L) across the full study period, modeled with SPDY (days since supplement initiation) as a continuous predictor. A positive value indicates increasing TAC over time.
SecondaryOxidative Stress Measured by Uric Acid Levels.

Uric acid is an antioxidant and levels of uric acid have been reported to be lower in ALS subjects and correlated with progression. It has also been shown to be responsive to treatments in trials

Time frame:
Baseline, 3 months, 5 months, and 9 months
Reported as:
Mean · mg/dL
Oxidative Stress Measured by Uric Acid Levels.
mg/dLNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Baseline10.0 ± 3.09.9 ± 2.08.7 ± 3.38.8 ± 1.8
3 months10.2 ± 2.79.5 ± 2.410.2 ± 2.810.4 ± 2.6
5 months11.1 ± 3.111.1 ± 3.110.4 ± 2.211.3 ± 2.9
9 months7.5 ± NA8.7 ± 1.17.0 ± 1.57.2 ± 1.6
Statistical analysis
  • Neuroinflammation vs Oxidative Stress vs Impaired Autophagy and Axonal Transport vs Mitochondrial Dysfunction · Mixed Models Analysis · p = 0.006 (Two-sided test of the SPDY main effect (slope = 0) from a linear mixed-effects model. P-values were adjusted using the Benjamin-Hochberg false discovery rate (FDR) procedure; the value reported is the FDR-adjusted q-value.) · Slope: -0.00300 · 95% CI -0.00505 to -0.00095Estimate represents the daily rate of change in Uric Acid (mg/dL) across the full study period, modeled with SPDY (days since supplement initiation) as a continuous predictor. A negative value indicates decreasing Uric Acid over time.
SecondaryMitochondrial Dysfunction Measured by Lactate

Compromised mitochondrial oxidative phosphorylation shifts the cellular bioenergetic system to anaerobic respiration and increases the level of lactate. Lactate has been used as a biomarker for mitochondrial disease in many previous studies.

Time frame:
Baseline, 3 months, 5 months, and 9 months
Reported as:
Mean · mmol/L
Mitochondrial Dysfunction Measured by Lactate
mmol/LNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Baseline5.8 ± 1.06.3 ± 1.26.7 ± 1.36.3 ± 1.4
3 months8.0 ± 1.37.2 ± 1.27.3 ± 1.37.6 ± 1.1
5 months9.6 ± 1.216.7 ± 5.414.6 ± 5.915.2 ± 6.3
9 months6.4 ± NA7.2 ± 2.47.8 ± 1.77.2 ± 1.4
Statistical analysis
  • Neuroinflammation vs Oxidative Stress vs Impaired Autophagy and Axonal Transport vs Mitochondrial Dysfunction · Mixed Models Analysis · p = 0.006 (Two-sided test of the SPDY main effect (slope = 0) from a linear mixed-effects model. P-values were adjusted using the Benjamin-Hochberg false discovery rate (FDR) procedure; the value reported is the FDR-adjusted q-value.) · Slope: 0.015 · 95% CI 0.00452 to 0.025Estimate represents the daily rate of change in Lactate (mM) across the full study period, modeled with SPDY (days since supplement initiation) as a continuous predictor. A positive value indicates increasing Lactate over time.
Other pre-specifiedImpaired Autophagy Measured by Beclin-1

To measure impaired autophagy, we will use Beclin-1. This highly conserved eukaryotic protein has a major regulatory role in autophagy. It is a component of the phosphatidylinositol-3-kinase (PI3K) complex which mediates vesicle-trafficking thereby inducing autophagy. Beclin-1 dysfunction has been implicated in many disorders, including cancer and neurodegenerative diseases.

Time frame:
Baseline, 3 months, 5 months, and 9 months

Results for this outcome have not been posted.

Other pre-specifiedNeuroinflammation Measured by Chitotriosidase (CHIT1)

Used to measure neuroinflammation. CHIT1 is known to be abnormal in patients with ALS, its levels correlate with disease progression and they can be altered by drugs in trials.

Time frame:
Baseline, 3 months, 5 months and 9 months

Results for this outcome have not been posted.

Adverse events

Collected over Up to approximately 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Neuroinflammation0/3 (0%)0/3 (0%)1/3 (33.3%)
Oxidative Stress0/15 (0%)0/15 (0%)15/15 (100%)
Impaired Autophagy and Axonal Transport1/14 (7.1%)1/14 (7.1%)14/14 (100%)
Mitochondrial Dysfunction2/18 (11.1%)2/18 (11.1%)18/18 (100%)
Most frequent serious events
Most frequent serious events
EventNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
Lung InfectionRespiratory, thoracic and mediastinal disorders0/30/150/142/18
Respiratory failureRespiratory, thoracic and mediastinal disorders0/30/150/142/18
Heart AttackCardiac disorders0/30/151/140/18
MeningitisInfections and infestations0/30/151/140/18
FallInjury, poisoning and procedural complications0/30/151/140/18
Cardiac DisorderCardiac disorders0/30/151/140/18
Kidney StonesRenal and urinary disorders0/30/151/140/18
Thromboembolic EventCardiac disorders0/30/150/141/18
SepsisInfections and infestations0/30/150/141/18
DiverticulitisGastrointestinal disorders0/30/150/141/18
Most frequent other events
Showing 10 of 34
Most frequent other events
EventNeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial Dysfunction
FallInjury, poisoning and procedural complications1/315/1514/1412/18
Upper respiratory infectionInfections and infestations0/32/155/142/18
InsomniaGeneral disorders1/30/150/140/18
Gastrointestinal DisorderGastrointestinal disorders0/31/150/145/18
Pain in extremityGeneral disorders0/30/153/140/18
Nasal congestionGeneral disorders0/30/152/140/18
NauseaGastrointestinal disorders0/30/152/140/18
Urinary respiratory tract infectionInfections and infestations0/32/150/140/18
Sore throatGeneral disorders0/30/150/142/18
Allergic rhinitisRespiratory, thoracic and mediastinal disorders0/30/151/140/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)NeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial DysfunctionTotal
Mean65.6 ± 5.758.2 ± 10.049.6 ± 10.659.3 ± 16.556.7 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)NeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial DysfunctionTotal
Female235616
Male11291234
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial DysfunctionTotal
Hispanic or Latino01102
Not Hispanic or Latino314131848
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial DysfunctionTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White313141848
More than one race00000
Unknown or Not Reported02002
Region of Enrollment
Region of Enrollment(Participants)NeuroinflammationOxidative StressImpaired Autophagy and Axonal TransportMitochondrial DysfunctionTotal
United States315141850
08

Study locations

2 sites
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Temple University
    Philadelphia, Pennsylvania 19122, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in May 2025, 11 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's 11 months is below that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
May 24, 2024
StartActual
Jun 12, 2024
Primary completionActual
May 22, 2025
CompletionActual
Jun 24, 2025
Results first posted
Oct 27, 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 27, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameALS Functional Rating Scale, Revised (ALSFRS-R)baseline and at each of the subsequent 9 telephone or in person visits (approximately 9 months) → Baseline, month 3, month 5, and month 9
  • DescriptionALS Functional Rating Scale, Revised (ALSFRS-R): how it is measured was reworded
Oct 27, 2026
Documents
Secondary outcomes
6 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedNeurofilament Light Chain levelsLevelsTime frame: baseline, month 3, month 5 (2 months into treatment) and month 9 (6 months into treatment) → Baseline, month 3, month 5 (2 months into treatment) and month 9 (6 months into treatment)
  • EditedNeuroinflammation measuredMeasured by C-reactive proteinProtein (CRP)Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months and 9 months
  • EditedNeuroinflammation measuredMeasured by monocyte chemoattractant proteinMonocyte Chemoattractant Protein-1 (MCP-1), Also Known as CCL2Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months and 9 months
  • EditedOxidative stress measuredStress Measured by total antioxidant capacityTotal Antioxidant Capacity (TAC)Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months, and 9 months
  • EditedOxidative stress measuredStress Measured by uric acid levelsUric Acid Levels.Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months, and 9 months
  • EditedMitochondrial dysfunction measuredDysfunction Measured by lactate.LactateTime frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months, and 9 months
  • RemovedNeuroinflammation measured by chitotriosidase (CHIT1)Time frame: baseline, 3 months, 5 months and 9 months
  • RemovedImpaired autophagy measured by Beclin-1Time frame: baseline, 3 months, 5 months and 9 months
  • Addedother outcomeImpaired Autophagy Measured by Beclin-1Time frame: Baseline, 3 months, 5 months, and 9 months
  • Addedother outcomeNeuroinflammation Measured by Chitotriosidase (CHIT1)Time frame: Baseline, 3 months, 5 months and 9 months
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Results posted
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameALS Functional Rating Scale, Revised (ALSFRS-R)baseline and at each of the subsequent 9 telephone or in person visits (approximately 9 months) → Baseline, month 3, month 5, and month 9
    • DescriptionALS Functional Rating Scale, Revised (ALSFRS-R): how it is measured was reworded
    Secondary outcomes 6 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedNeurofilament Light Chain levelsLevelsTime frame: baseline, month 3, month 5 (2 months into treatment) and month 9 (6 months into treatment) → Baseline, month 3, month 5 (2 months into treatment) and month 9 (6 months into treatment)
    • EditedNeuroinflammation measuredMeasured by C-reactive proteinProtein (CRP)Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months and 9 months
    • EditedNeuroinflammation measuredMeasured by monocyte chemoattractant proteinMonocyte Chemoattractant Protein-1 (MCP-1), Also Known as CCL2Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months and 9 months
    • EditedOxidative stress measuredStress Measured by total antioxidant capacityTotal Antioxidant Capacity (TAC)Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months, and 9 months
    • EditedOxidative stress measuredStress Measured by uric acid levelsUric Acid Levels.Time frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months, and 9 months
    • EditedMitochondrial dysfunction measuredDysfunction Measured by lactate.LactateTime frame: baseline, 3 months, 5 months and 9 months → Baseline, 3 months, 5 months, and 9 months
    • RemovedNeuroinflammation measured by chitotriosidase (CHIT1)Time frame: baseline, 3 months, 5 months and 9 months
    • RemovedImpaired autophagy measured by Beclin-1Time frame: baseline, 3 months, 5 months and 9 months
    • Addedother outcomeImpaired Autophagy Measured by Beclin-1Time frame: Baseline, 3 months, 5 months, and 9 months
    • Addedother outcomeNeuroinflammation Measured by Chitotriosidase (CHIT1)Time frame: Baseline, 3 months, 5 months and 9 months
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06429059
Lead sponsor
Duke University
Collaborators
Temple University
Responsible party
Sponsor
First posted
May 24, 2024
Start date
Jun 12, 2024
Primary completion
May 22, 2025
Completion
Jun 24, 2025
Results posted
Oct 27, 2026
Last update
Oct 27, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Astaxanthine · Protandim · Melatonin · Mitoquinone

Start the discussion